Galectin Therapeutics Inc <GALT.OQ> expected to post a loss of 16 cents a share - Earnings Preview
Galectin Therapeutics Inc GALT.OQ GALT.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Galectin Therapeutics Inc is for a loss of 16 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Galectin Therapeutics Inc is $6.00, about 36% above its last closing price of $3.84
This summary was machine generated August 8 at 16:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Investing in Artificial General Intelligence (AGI)
AGI promises transformative productivity and economic gains but carries unprecedented technical, ethical, and social risks.Significant exposure comes through tech giants, semiconductor leaders, and cloud infrastructure providers, fueling AGI research.
Investing in Edge Computing
Edge computing complements the cloud by reducing latency, saving bandwidth, and enhancing privacy for real-time applications. Growth is fueled by IoT expansion, 5G rollout, AI integration, and enterprise digital transformation.
Berkshire Hathaway FY2025 Second Quarter Earnings Comments
TradingKey - Revenue: In Q2 2025, Berkshire's total revenue was $92.515 billion, slightly down from $93.653 billion in the same period last year, falling short of market expectations.
[Reuters Analysis] Fed's reticence on rate cuts forces market to rethink outlook
Traders back away from bets on interest rate cut in SeptemberTreasury yields and the dollar rise, while stocks retreatPositioning ahead of Fed decision may have amplified bond reactionInvestors warn against reading too much into one-day market reactionBy Saqib Iqbal Ahmed and Davide Barbuscia NEW
